FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024149631> ?p ?o ?g. }

• W2024149631 endingPage "70" @default.
• W2024149631 startingPage "60" @default.
• W2024149631 abstract "BACKGROUND Prostate cancer is the most frequently diagnosed malignancy and the second-leading cause of cancer death in men. The purpose of this study was to determine the anti-proliferative and anti-angiogenic efficacy of angiotensin-(1-7) [Ang-(1-7)], an endogenous peptide hormone, in human prostate cancer xenografts. METHODS Human LNCaP prostate cancer cells were injected into the flank of athymic mice and tumors were treated with Ang-(1-7) for 54 days. Tumor growth and angiogenesis were determined by immunohistochemistry and western blot hybridization. RESULTS Ang-(1-7) markedly reduced the volume and wet weight of LNCaP xenograft tumors. Histological analysis of tumor sections from saline-treated mice showed increased Ki67 immunoreactivity and enhanced phosphorylation of the MAP kinases ERK1/2 compared to tumors from Ang-(1-7)-treated mice, suggesting that the heptapeptide reduces cell proliferation. Intratumoral vessel density was decreased in Ang-(1-7)-treated mice with an associated reduction in vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), suggesting that the heptapeptide attenuates vascularization by reducing angiogenic factors. Ang-(1-7) administration markedly increased the soluble fraction of VEGF receptor 1 (sFlt-1), with a concomitant reduction in VEGF receptors 1 and 2. sFlt-1 serves as a decoy receptor that traps VEGF and PlGF, making the ligands unavailable to membrane-bound VEGF receptors and preventing activation of pro-angiogenic signaling. CONCLUSIONS The decrease in PlGF and VEGF coupled with the increase in sFlt-1 suggests that Ang-(1-7) may serve as a novel anti-angiogenic therapy for prostate cancer. Further, the pleiotropic mechanisms of action by Ang-(1-7) may limit angiogenic resistance that occurs with VEGF inhibitors or receptor blockers. Prostate 73: 60–70, 2013. © 2012 Wiley Periodicals, Inc." @default.
• W2024149631 created "2016-06-24" @default.
• W2024149631 creator A5050402949 @default.
• W2024149631 creator A5057203129 @default.
• W2024149631 creator A5064049204 @default.
• W2024149631 creator A5087773842 @default.
• W2024149631 date "2012-05-29" @default.
• W2024149631 modified "2023-09-26" @default.
• W2024149631 title "Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1" @default.
• W2024149631 cites W1522523413 @default.
• W2024149631 cites W1969492598 @default.
• W2024149631 cites W1970068637 @default.
• W2024149631 cites W1975198479 @default.
• W2024149631 cites W1975616973 @default.
• W2024149631 cites W1978998472 @default.
• W2024149631 cites W1979387004 @default.
• W2024149631 cites W1980725734 @default.
• W2024149631 cites W1980946326 @default.
• W2024149631 cites W1982983286 @default.
• W2024149631 cites W1986469266 @default.
• W2024149631 cites W1995955591 @default.
• W2024149631 cites W1997410071 @default.
• W2024149631 cites W1998984120 @default.
• W2024149631 cites W2001775125 @default.
• W2024149631 cites W2003801328 @default.
• W2024149631 cites W2010430961 @default.
• W2024149631 cites W2016569548 @default.
• W2024149631 cites W2026783909 @default.
• W2024149631 cites W2027511653 @default.
• W2024149631 cites W2034017362 @default.
• W2024149631 cites W2049820493 @default.
• W2024149631 cites W2053975077 @default.
• W2024149631 cites W2067142583 @default.
• W2024149631 cites W2067153979 @default.
• W2024149631 cites W2069944883 @default.
• W2024149631 cites W2070976146 @default.
• W2024149631 cites W2078051927 @default.
• W2024149631 cites W2083529118 @default.
• W2024149631 cites W2094546405 @default.
• W2024149631 cites W2100527908 @default.
• W2024149631 cites W2106321093 @default.
• W2024149631 cites W2107950465 @default.
• W2024149631 cites W2110943754 @default.
• W2024149631 cites W2113801726 @default.
• W2024149631 cites W2114435925 @default.
• W2024149631 cites W2119281341 @default.
• W2024149631 cites W2119562899 @default.
• W2024149631 cites W2133466283 @default.
• W2024149631 cites W2137248091 @default.
• W2024149631 cites W2142080475 @default.
• W2024149631 cites W2144707486 @default.
• W2024149631 cites W2151166210 @default.
• W2024149631 cites W2151190145 @default.
• W2024149631 cites W2168356290 @default.
• W2024149631 cites W2168427108 @default.
• W2024149631 cites W2183415855 @default.
• W2024149631 cites W4211253280 @default.
• W2024149631 doi "https://doi.org/10.1002/pros.22540" @default.
• W2024149631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22644934" @default.
• W2024149631 hasPublicationYear "2012" @default.
• W2024149631 type Work @default.
• W2024149631 sameAs 2024149631 @default.
• W2024149631 citedByCount "55" @default.
• W2024149631 countsByYear W20241496312013 @default.
• W2024149631 countsByYear W20241496312014 @default.
• W2024149631 countsByYear W20241496312015 @default.
• W2024149631 countsByYear W20241496312016 @default.
• W2024149631 countsByYear W20241496312017 @default.
• W2024149631 countsByYear W20241496312018 @default.
• W2024149631 countsByYear W20241496312019 @default.
• W2024149631 countsByYear W20241496312020 @default.
• W2024149631 countsByYear W20241496312021 @default.
• W2024149631 countsByYear W20241496312022 @default.
• W2024149631 countsByYear W20241496312023 @default.
• W2024149631 crossrefType "journal-article" @default.
• W2024149631 hasAuthorship W2024149631A5050402949 @default.
• W2024149631 hasAuthorship W2024149631A5057203129 @default.
• W2024149631 hasAuthorship W2024149631A5064049204 @default.
• W2024149631 hasAuthorship W2024149631A5087773842 @default.
• W2024149631 hasConcept C121608353 @default.
• W2024149631 hasConcept C126322002 @default.
• W2024149631 hasConcept C134018914 @default.
• W2024149631 hasConcept C167734588 @default.
• W2024149631 hasConcept C170493617 @default.
• W2024149631 hasConcept C2776235491 @default.
• W2024149631 hasConcept C2776871010 @default.
• W2024149631 hasConcept C2777025900 @default.
• W2024149631 hasConcept C2779723316 @default.
• W2024149631 hasConcept C2780192828 @default.
• W2024149631 hasConcept C2780394083 @default.
• W2024149631 hasConcept C2908929049 @default.
• W2024149631 hasConcept C502942594 @default.
• W2024149631 hasConcept C71924100 @default.
• W2024149631 hasConceptScore W2024149631C121608353 @default.
• W2024149631 hasConceptScore W2024149631C126322002 @default.
• W2024149631 hasConceptScore W2024149631C134018914 @default.
• W2024149631 hasConceptScore W2024149631C167734588 @default.
• W2024149631 hasConceptScore W2024149631C170493617 @default.

• next